Sonoco Products Company

▲ Bull Case

• ◆P/E re-rating from 7.9x trough to 12x+ normalized multiple: S&P 500 Dividend Aristocrats trade at median 14–16x P/E over 20-year periods. At 7.9x, SON is at the 5th percentile historically. At 12x FY2028E EPS of $8.50, the stock reaches $102 — a +117% return from $46.94 — on zero fundamental surprise, purely from multiple normalization as leverage declines below 2.5x and institutional income mandates re-enter the name.
• ◆Eviosys synergy delivery ($100M target by FY2027) + EMEA metal can oligopoly value: Management guided $100M in procurement and SG&A synergies from Eviosys. The 12-month-ahead-of-schedule deleveraging is the strongest proxy for synergy realization. Full synergy delivery adds approximately $0.65–0.80/share to EPS by FY2027, supporting the $7.75 EPS estimate and validating the strategic logic of the acquisition. The EMEA metal food can market is an oligopoly (2–3 major players), providing structural pricing power unavailable in more fragmented packaging segments.
• ◆Sustainability regulatory tailwind (PPWR/EPR) is a 5–10 year unpriced structural driver: EU Packaging and Packaging Waste Regulation (PPWR) and Extended Producer Responsibility (EPR) regulations are mandating shifts from single-use plastics to fiber and metal packaging — precisely the two substrates at the core of Sonoco's business. This regulatory conversion creates demand growth for IPP and Eviosys metal cans regardless of macro conditions. Current valuations assign zero premium to this tailwind, creating asymmetric upside if even one major EU regulatory milestone is priced into packaging sector multiples.

▼ Bear Case

• ◆IPP cyclical deterioration extends through FY2026–2027: Industrial Paper Packaging volumes declined -6% YoY in Q1 2025. If global industrial production weakens further into recession, IPP organic volumes could deteriorate -8%+ for multiple consecutive quarters, keeping FY2026 EPS near $6.00 rather than recovering to $6.80 and delaying the multiple re-rating. Without IPP recovery, the earnings growth narrative stalls and the trough P/E persists.
• ◆Eviosys synergy shortfall and integration friction: A failure to deliver above $50M in FY2026 synergies (half of the $100M target) would signal that procurement scale benefits and SG&A rationalization are not materializing on schedule. Given that synergy delivery is the primary EBITDA growth driver for FY2026–FY2027, a shortfall would require downward revision of $0.60–0.80/share in EPS estimates and potentially reverse the deleveraging narrative if EBITDA disappoints.
• ◆Leverage reversal from macro shock or integration cost overruns: If Net Debt/EBITDA rises back above 3.5x due to unexpected integration costs, FCF shortfalls, or a macro-driven EBITDA decline, the investment thesis is structurally impaired. A return to 3.5x+ leverage would contradict the management execution narrative, likely trigger credit concerns, and compress the multiple further rather than allowing re-rating. Bear case price target: ~$45/share; however, 31-month dividend income of ~$5.80 makes the bear total return approximately +$3.86, meaning the yield provides a complete income buffer against the bear price scenario.

“The central Wall Street debate on SON is whether the trough 7.9x P/E represents a temporary dislocation (BUY thesis) or a structural re-rating to a lower multiple permanently justified by higher leverage, reduced business quality post-divestiture, and macro headwinds to IPP. Bulls argue that Dividend Aristocrat mean reversion is statistically robust over 20-year periods and that the 12-months-ahead-of-schedule delevering is a decisive management quality signal that should force multiple re-rating as leverage crosses 2.5x. Bears counter that (a) SON divested its highest-margin businesses (TFP, ThermoSafe) to fund Eviosys, structurally reducing EBITDA quality; (b) Eviosys is a capital-intensive, commodity-adjacent business that deserves a lower multiple than the divested specialty businesses; and (c) IPP is in secular decline as digital media and changing industrial production patterns reduce demand for paper tubes and cores. A secondary debate concerns the reliability of analyst consensus EPS estimates ($6.80 FY2026E) given the absence of management transcript guidance — bears argue the estimates embed optimistic synergy assumptions without direct management confirmation, while bulls note the delevering proxy (achieving 3.0x vs. 3.5x–4.0x expected) validates underlying EBITDA generation above consensus models.”

• ◆Net Debt/EBITDA confirmed ≤2.5x (Q2/Q3 2026) — primary re-rating trigger enabling institutional income mandate re-entry and potential credit upgrade
• ◆Eviosys synergy disclosure reaching $25M+ per quarter run rate in any FY2026 quarterly earnings release
• ◆43rd consecutive annual dividend increase announced (Q4 2026) — confirms management confidence in FCF trajectory
• ◆IPP organic volume turning positive YoY in any FY2026–2027 quarter — removes cyclical overhang narrative
• ◆Buyback initiation announcement when leverage <2.0x (potential FY2027) — adds $0.40–0.60/share EPS accretion
• ◆Potential M&A approach at $80–90+/share (10–12x EV/EBITDA control premium) from CCK, SLGN, or private equity

• ◆IPP organic volume declines >8% YoY for two consecutive quarters (Kill Switch #4) — signals structural not cyclical demand deterioration
• ◆Annual dividend increase streak broken — flat or cut dividend triggers 50% position reduction (Kill Switch #1); breaks the primary quality thesis anchor
• ◆Net Debt/EBITDA rises above 3.5x on any quarterly LTM basis (Kill Switch #2) — contradicts management execution narrative and triggers 40% reduction
• ◆Eviosys synergy realization below $50M for full-year FY2026 (Kill Switch #3) — requires $0.60–0.80/share EPS downgrade and 30% position reduction
• ◆CEO Coker sells >$5M personal SON shares in any 6-month window (Kill Switch #5) — insider conviction signal; triggers 25% reduction and investigation
• ◆Global recession deepening IPP trough and delaying FY2026–2027 EPS recovery to $6.80–$7.75 range
• ◆Transcripts unavailable limitation: Eviosys synergy and leverage guidance specificity unconfirmed by direct management commentary — consensus estimates may embed optimistic assumptions